Business Context and Reporting Period
This Form 8-K filing by Imara Inc. (IMRA) reports events occurring on November 9 and November 10, 2022. The Company, an emerging growth company incorporated in Delaware, completed the sale of its PDE9 program assets, including tovinontrine (IMR-687), to Cardurion Pharmaceuticals, Inc. The transaction was approved by stockholders at a special meeting held on November 9, 2022, and consummated on November 10, 2022.
Key Financial Metrics and Transaction Details
The filing details a significant asset disposition rather than standard operating financial results. Key financial terms of the Asset Sale include:
- Upfront Cash Payment: $34,750,000 received upon closing.
- Prior Payment: $250,000 previously paid by Cardurion upon execution of a non-binding term sheet.
- Potential Clinical Milestone: Up to $10,000,000 payable upon achievement of proof of concept or other specified clinical milestones.
- Potential Regulatory/Commercial Milestone: Up to $50,000,000 payable upon achievement of specified regulatory and/or commercial events.
- Total Potential Consideration: Up to $95,000,000.
The filing does not provide current period revenue, profit, cash flow, margins, or debt levels. Pro forma financial information is expected to be filed in an amendment within four business days of the closing.
Material Changes
The primary material change is the divestiture of the Company's PDE9 program assets. This transaction represents a strategic shift, converting a development asset into immediate liquidity and contingent future value. The Company received $34.75 million in cash, significantly altering its liquidity position compared to the pre-transaction state.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the transaction's completion and the successful approval by stockholders. The future value of the deal is contingent on Cardurion achieving specific clinical and commercial milestones; failure to meet these targets would result in no further payments beyond the upfront cash. The filing notes that the Company intends to file pro forma financial information to reflect the impact of this transaction.
Investor Verification Checklist
- Verify the receipt of the $34,750,000 upfront payment in the Company's cash balance.
- Review the upcoming amendment to this 8-K for pro forma financial statements.
- Examine the Asset Purchase Agreement (Exhibit 2.1) for specific definitions of the clinical and commercial milestones required to trigger the $60 million in potential future payments.
- Confirm the Company's remaining cash runway and operational focus following the divestiture of the PDE9 program.